The report was uncontrolled, unblinded, not randomized, had no comparator arm, used patient-reported outcomes rather than validated pain instruments, and did not publish dose, effect size, confidence intervals, p-values, or systematically collected adverse events limitations that severely constrain any clinical inference
Lawyers were still speculating on a potential global settlement
Federal law doesn't require states to cover anti-obesity drugs, which means: Only ~25% of states (13 of 51) cover GLP-1 (glucagon-like peptide-1) weight loss medications like Wegovy [1][2][9] Coverage is shrinking several states are ending or restricting coverage in 2025-2026 [8] Even in states with coverage , strict prior authorization requirements applyyour doctor must get approval before the medication is covered [13] Diabetes coverage is different GLP-1 medications are typically covered for type 2 diabetes in all states [10] Bottom line: If you have Medicaid, your coverage depends entirely on your state's policies
The weight loss isn't just about numbers on a scale
Our program is built around a simple idea: medicine works best when a real physician knows your name, knows your history, and is genuinely paying attention